Edema in Medical Technology
Navigation Links
Edema in Medical Technology
... Clinical Program for XERECEPT(R) in patients with edema associated with brain tumors and from preclinical ... of XERECEPT(R) in Patients with Cerebral edema Demonstrated Clinically Significant Reductions in ... standard of care in the treatment of cerebral edema associated with brain tumors, and an open-label ...
... pulmonary edema, and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%), and ... effusion or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain ... adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle cramps ...
... a Phase 2 study in patients with Diabetic Macular edema (DME). Enrollment in the wet AMD and DME studies ... the underlying biology of CRVO is related to edema and the growth of abnormal new blood vessels that ... may help decrease vascular permeability and edema and prevent the growth of abnormal new blood ...
... retention (e.g., pleural effusion, pulmonary edema and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%) and ... adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle cramps ...
... or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain ... adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle ... pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the ...
... Medidur FA for the treatment of diabetic macular edema (DME). FAME is two, duplicate, double-masked, ... years as a treatment for diabetic macular edema (DME). Using a proprietary 25 gauge injector ... diabetic retinopathy, of which diabetic macular edema is the primary cause of vision loss. In ...
... patients with wet (exudative) age-related macular edema (wet AMD). Similar to its Phase 1 study in patients with diabetic macular edema (DME), preliminary results from this prospective ... (wet AMD) and the treatment of diabetic macular edema (DME), a manifestation of diabetic ...
... chronic, clinically significant diabetic macular edema (DME). Results from this prospective study of 50 ... pathway rather than simply reversing macular edema in a more non-specific way," said Dr. ... compliance and safety. About Diabetic Macular edema Diabetic ...
... events. In this trial, occurrence of drug-related AEs included: peripheral edema (2.2 percent) and dizziness (1.1 percent). High blood pressure can ... (5/40 mg), 13.3 percent (10/20 mg), and 11.2 percent (10/40 mg). The edema incidence for placebo was 12.3 percent. Adverse reactions seen at ...
... microplasmin intravitreal injection for the treatment of Diabetic Macular edema (MIVI II DME). This trial is designed as the initial step in evaluating ... the leading cause of blindness in patients aged 20-60. Diabetic Macular edema (DME) is a condition where swelling of the retina occurs in patients with ...
... anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), ... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), ...
... (e.g., pleural effusion, pulmonary edema, and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%), and musculoskeletal pain (2%-9%) were ... most frequently reported adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle cramps (28%-62%), vomiting (23%-58%), ...
... anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), ... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), ...
... anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), ... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), ...
... only if clinically indicated. The type of treatment will depend on whether edema or hypotension is the primary clinical problem. Pre-existing low serum ... (64%), transaminase increase (61%), infection (48%), pain (48%), edema (47%), hypotension (36%), anorexia (36%), and rash (34%). ...
... frequency in the three treatment groups. There was one case of peripheral edema in the placebo arm and one case of peripheral edema in one of the treated arms. There were no increases in liver enzymes above ...
... HYLENEX-assisted arms, the HYLENEX arms demonstrated significantly less edema in all HYLENEX dose groups and all timepoints during infusions. Across the three HYLENEX dose cohorts, 94% of subjects had moderate or severe arm edema with placebo compared to 17% with HYLENEX (p < 0.0001). AEs occurring ...
... times daily, when used for 3 months in the treatment of cystoid macular edema (CME) following uncomplicated cataract surgery. Poster Presentations at ... Versus Ketorolac in the Treatment of Acute Pseudophakic Cystoid Macular edema Contributing authors: David S. Rho, MD, Rochelle E. Tractenberg, ...
... effects, especially that of capillary leak syndrome where leakage of fluid from the blood results in dangerously low blood pressure (hypotension), edema and multiple organ failure. Capillary leak syndrome affects as many as 65% of patients and can lead to the cessation of therapy. Dr. Epstein has ...
... or for prevention of heart disease or stroke Take insulin or nitrate medicines Have a type of diabetic eye disease called macular edema Have liver problems or had liver problems while taking REZULIN(R) (troglitazone) Are pregnant or planning to become pregnant ...
... bacterium. The investigational antibody is designed to target a protein component known as the anthrax Protective Antigen (PA) of the lethal and edema toxin complexes produced by the bacterium. Preclinical studies suggest that Valortim(R) has the potential to provide significant protection against ...
... G.L. Torkildsen, J.I. Williams, P.J. Gomes, M.B. Abelson, T.R. McNamara Bromfenac for the Treatment of Chronic Pseudophakic Cystoid Macular edema Author: E.F. Kadrmas Stability of Vitrase(R) Solutions after Dilution in Anesthetics Authors: B.A. Aird, J.D. Dahlstrom, G.A. Baklayan, ....
... (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or loss of vision, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema). Adverse reactions reported during post-approval use of PEGASYS therapy, ...
... (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or loss of vision, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema). Adverse reactions reported during post-approval use of PEGASYS therapy, with ...
... Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular edema (DME) under the current protocol, without change. The Board completed its final review of the currently available safety and efficacy data prior to ...
... reported adverse events among exenatide once weekly and sitagliptin users were nausea and diarrhea. Upper respiratory tract infection and peripheral edema were the most frequently reported events by patients receiving pioglitazone. Study Design The 26-week double-blind, superiority study ...
... first human pharmacokinetic study (PK Study) of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME). This 36-month, open-label, Phase 2 study, running concurrently with the pivotal Phase 3 FAME(TM) Study (Fluocinolone Acetonide in ...
... (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain ...
... group (greater than four hours). In the open label study of Cinryze as treatment for acute attacks of HAE, no patients who had acute laryngeal edema attacks required hospitalization or intubation. Cinryze was generally well tolerated. There were no deaths or serious adverse reactions related to ...
... The most commonly reported adverse events (all grades; >10% patients) in the study included, stomatitis, anorexia, fatigue, rash, nausea, edema peripheral, thrombocytopenia, diarrhea, pruritus, anemia, dysgeusia, vomiting, pyrexia, pneumonitis, constipation and insomnia. Serious adverse ...
... patients. Furthermore, our siRNA drug candidate, PF-4523655, has been advanced into two Phase II clinical trials -- one for diabetic macular edema and the other for age related macular degeneration -- by our licensee, Pfizer. In addition, we recently announced that our QPI-1007 drug candidate, ...
... pulmonary edema, and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%), and ... effusion or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain ... adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle cramps ...
... a Phase 2 study in patients with Diabetic Macular edema (DME). Enrollment in the wet AMD and DME studies ... the underlying biology of CRVO is related to edema and the growth of abnormal new blood vessels that ... may help decrease vascular permeability and edema and prevent the growth of abnormal new blood ...
... retention (e.g., pleural effusion, pulmonary edema and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%) and ... adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle cramps ...
... or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain ... adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle ... pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the ...
... Medidur FA for the treatment of diabetic macular edema (DME). FAME is two, duplicate, double-masked, ... years as a treatment for diabetic macular edema (DME). Using a proprietary 25 gauge injector ... diabetic retinopathy, of which diabetic macular edema is the primary cause of vision loss. In ...
... patients with wet (exudative) age-related macular edema (wet AMD). Similar to its Phase 1 study in patients with diabetic macular edema (DME), preliminary results from this prospective ... (wet AMD) and the treatment of diabetic macular edema (DME), a manifestation of diabetic ...
... chronic, clinically significant diabetic macular edema (DME). Results from this prospective study of 50 ... pathway rather than simply reversing macular edema in a more non-specific way," said Dr. ... compliance and safety. About Diabetic Macular edema Diabetic ...
Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
... from the leading type 2 diabetic therapies include weight gain and edema as well as the potential for congestive heart failure and bone loss. ... patients from the adverse side effects of current treatments, including edema and weight gain. The company's scientific strategy is built on a ...... events. In this trial, occurrence of drug-related AEs included: peripheral edema (2.2 percent) and dizziness (1.1 percent). High blood pressure can ... (5/40 mg), 13.3 percent (10/20 mg), and 11.2 percent (10/40 mg). The edema incidence for placebo was 12.3 percent. Adverse reactions seen at ...
... microplasmin intravitreal injection for the treatment of Diabetic Macular edema (MIVI II DME). This trial is designed as the initial step in evaluating ... the leading cause of blindness in patients aged 20-60. Diabetic Macular edema (DME) is a condition where swelling of the retina occurs in patients with ...
... anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), ... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), ...
... (e.g., pleural effusion, pulmonary edema, and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%), and musculoskeletal pain (2%-9%) were ... most frequently reported adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle cramps (28%-62%), vomiting (23%-58%), ...
... anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), ... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), ...
... anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), ... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), ...
... only if clinically indicated. The type of treatment will depend on whether edema or hypotension is the primary clinical problem. Pre-existing low serum ... (64%), transaminase increase (61%), infection (48%), pain (48%), edema (47%), hypotension (36%), anorexia (36%), and rash (34%). ...
BioElectronics Announces Major Clinical Trials
... are starting to investigate the use of ActiPatch for post-surgical edema and pain control, but there has been little clinical data. We look forward ... drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved ...... frequency in the three treatment groups. There was one case of peripheral edema in the placebo arm and one case of peripheral edema in one of the treated arms. There were no increases in liver enzymes above ...
InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
... studies, wherein an absence of recognized TZD adverse effects such as edema offers a genuine breakthrough for this target," said Linda Slanec Higgins, ... in humans and offers the opportunity for disease modification without the edema and weight gain of current TZD therapies," said Alex DePaoli, MD, ...... HYLENEX-assisted arms, the HYLENEX arms demonstrated significantly less edema in all HYLENEX dose groups and all timepoints during infusions. Across the three HYLENEX dose cohorts, 94% of subjects had moderate or severe arm edema with placebo compared to 17% with HYLENEX (p < 0.0001). AEs occurring ...
... times daily, when used for 3 months in the treatment of cystoid macular edema (CME) following uncomplicated cataract surgery. Poster Presentations at ... Versus Ketorolac in the Treatment of Acute Pseudophakic Cystoid Macular edema Contributing authors: David S. Rho, MD, Rochelle E. Tractenberg, ...
Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
... potential to improve and stabilize visual acuity and to reduce retinal edema in patients with diabetic maculopathy and macular edema without causing any damage to the photoreceptors. Peter Hamilton, MD, ...... effects, especially that of capillary leak syndrome where leakage of fluid from the blood results in dangerously low blood pressure (hypotension), edema and multiple organ failure. Capillary leak syndrome affects as many as 65% of patients and can lead to the cessation of therapy. Dr. Epstein has ...
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
... withdrawal. The most common adverse events in the study were: upper respiratory tract infection (glargine 149 [29%], NPH 169 [33.6%]), peripheral edema (glargine 103 [20%], NPH 114 [22.7%]), and arthralgia (glargine 73 [14.2%], NPH 81 [16.1%]). About the study This long-term study was ...New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
... (AEs) were comparable among the 3 treatment arms. The most frequently reported AEs included upper respiratory tract infections (5.2%), peripheral edema (4.1%), pain in extremity (3.8%), nasopharyngitis (3.5%), sinusitis (3.2%), and back pain (3.2%). A greater but nonsignificant proportion of patients ...... or for prevention of heart disease or stroke Take insulin or nitrate medicines Have a type of diabetic eye disease called macular edema Have liver problems or had liver problems while taking REZULIN(R) (troglitazone) Are pregnant or planning to become pregnant ...
... bacterium. The investigational antibody is designed to target a protein component known as the anthrax Protective Antigen (PA) of the lethal and edema toxin complexes produced by the bacterium. Preclinical studies suggest that Valortim(R) has the potential to provide significant protection against ...
... G.L. Torkildsen, J.I. Williams, P.J. Gomes, M.B. Abelson, T.R. McNamara Bromfenac for the Treatment of Chronic Pseudophakic Cystoid Macular edema Author: E.F. Kadrmas Stability of Vitrase(R) Solutions after Dilution in Anesthetics Authors: B.A. Aird, J.D. Dahlstrom, G.A. Baklayan, ....
ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert;
... and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids and hyperemia. Lacrisert should not be used by patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, ...... (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or loss of vision, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema). Adverse reactions reported during post-approval use of PEGASYS therapy, ...
... (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or loss of vision, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema). Adverse reactions reported during post-approval use of PEGASYS therapy, with ...
... Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular edema (DME) under the current protocol, without change. The Board completed its final review of the currently available safety and efficacy data prior to ...
... reported adverse events among exenatide once weekly and sitagliptin users were nausea and diarrhea. Upper respiratory tract infection and peripheral edema were the most frequently reported events by patients receiving pioglitazone. Study Design The 26-week double-blind, superiority study ...
Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies
... (HAE) is estimated to afflict 10,000 people in the United States each year. Patients with HAE suffer from recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. Left untreated, most patients will suffer at least one acute attack per month. Chronic therapy with ...... first human pharmacokinetic study (PK Study) of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME). This 36-month, open-label, Phase 2 study, running concurrently with the pivotal Phase 3 FAME(TM) Study (Fluocinolone Acetonide in ...
... (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain ...
... group (greater than four hours). In the open label study of Cinryze as treatment for acute attacks of HAE, no patients who had acute laryngeal edema attacks required hospitalization or intubation. Cinryze was generally well tolerated. There were no deaths or serious adverse reactions related to ...
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
... but like any other surgery, problems may develop occasionally such as post-surgery inflammation. If poorly controlled, a condition called macular edema can be caused by inflammation, which when becoming chronic, leads to permanent damage to the retinal architecture and loss of visual acuity. ...... The most commonly reported adverse events (all grades; >10% patients) in the study included, stomatitis, anorexia, fatigue, rash, nausea, edema peripheral, thrombocytopenia, diarrhea, pruritus, anemia, dysgeusia, vomiting, pyrexia, pneumonitis, constipation and insomnia. Serious adverse ...
... patients. Furthermore, our siRNA drug candidate, PF-4523655, has been advanced into two Phase II clinical trials -- one for diabetic macular edema and the other for age related macular degeneration -- by our licensee, Pfizer. In addition, we recently announced that our QPI-1007 drug candidate, ...
Other Contentsfissionfissionbinarybinarybinarybinarybiochemicalbiochemicalbiochemicalbiochemicalbiochemicalbiochemicalbiochemicalbiochemicalbiogenesistissuestissuestissuestissuestissuestissuestissuestissuesbiologicsbiologicsbiomassbiomassbiomassbiomass
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Scientists discover gene module underlying atherosclerosis development 2How to read brain activity? 2APA Offers Free Resources for Public on Mental Health Parity Law 57232 1APA Offers Free Resources for Public on Mental Health Parity Law 57232 2Sono Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer 57229 1Sono Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer 57229 2HIPAA com Launches HIPAA TV 57226 1HIPAA com Launches HIPAA TV 57226 2
Breaking Medicine News(10 mins):Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3Health News:Prostate Hormone Therapy May Up Heart Risks 2Health News:Prostate Hormone Therapy May Up Heart Risks 3Health News:Pitt study suggests craving hinders comprehension without you realizing it 2Health News:EPA: Greenhouse Gases Hazardous to Your Health 2Health News:EPA: Greenhouse Gases Hazardous to Your Health 3Health News:Oncologist at the Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization 2Health News:Oncologist at the Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization 3Health News:Oncologist at the Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization 4
Other TagsCompCompCompCompCompCompCompCompSenaSenaMallMallMallMallMallMallOther Tagsafford 2afford 3afford 4afford 5afford 6afford 7afford 8afford 9afford 10stressed 2deadliest 2globe 2[1] Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure[0] Prostate Hormone Therapy May Up Heart Risks[0] Pitt study suggests craving hinders comprehension without you realizing it[0] EPA: Greenhouse Gases Hazardous to Your Health [1] Oncologist at the Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |